Outcomes according to treatment arm
| Outcome . | HR* . | 95% CI . | P . |
|---|---|---|---|
| Death before recurrent malignancy | 1.55 | 0.90-2.65 | .11 |
| Secondary immunosuppressive therapy | 0.73 | 0.38-1.37 | .35 |
| Discontinuation of immunosuppression | 1.17 | 0.86-1.58 | .32 |
| Recurrent malignancy | 1.17 | 0.68-2.02 | .57 |
| Mortality | 1.35 | 0.91-2.01 | .13 |
| Transplantation-related mortality or relapse | 1.51 | 1.03-2.21 | .03 |
| Outcome . | HR* . | 95% CI . | P . |
|---|---|---|---|
| Death before recurrent malignancy | 1.55 | 0.90-2.65 | .11 |
| Secondary immunosuppressive therapy | 0.73 | 0.38-1.37 | .35 |
| Discontinuation of immunosuppression | 1.17 | 0.86-1.58 | .32 |
| Recurrent malignancy | 1.17 | 0.68-2.02 | .57 |
| Mortality | 1.35 | 0.91-2.01 | .13 |
| Transplantation-related mortality or relapse | 1.51 | 1.03-2.21 | .03 |
Hazard ratios (HR) compare results for the CSP plus prednisone arm with those for the prednisone arm, with adjustments for sex of patient, GVHD prophylaxis, and type of onset. Results were similar to those reported in the table when disease risk and sex of patient/donor were added to the model (data not shown).